thalidomide has been researched along with Pancreatic Neoplasms in 22 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial." | 9.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 5.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| "Treatment with temozolomide and thalidomide was associated with an objective biochemical (chromogranin A) response rate of 40%, and a radiologic response rate of 25% (45% among pancreatic endocrine tumors, 33% among pheochromocytomas, and 7% among carcinoid tumors)." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. ( Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Michelini, A; Muzikansky, A; Ryan, DP; Stuart, K; Vincitore, M, 2006) |
| "Fifty patients with advanced pancreatic cancer who had lost at least 10% of their body weight were randomised to receive thalidomide 200 mg daily or placebo for 24 weeks in a single centre, double blind, randomised controlled trial." | 5.11 | Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. ( Duncan, HD; Ellis, RD; Goggin, PM; Gordon, JN; Johns, T; Trebble, TM, 2005) |
| " Herein, we report on a patient with pancreatic adenocarcinoma and metastatic disease treated with a combination regimen of gemcitabine and lenalidomide, without major complications." | 3.76 | Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. ( Dalgleish, AG; Liu, WM; Nizar, S, 2010) |
| "Patients with advanced pancreatic cancer were treated in first line with lenalidomide orally for 21 days of a 28 days cycle and the standard regimen for gemcitabine." | 2.84 | Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. ( Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ, 2017) |
| " The tolerability profile demonstrated in the dose escalation schedule of lenalidomide suggests the dosing of lenalidomide to be 25 mg daily on days 1-21 with standard dosing of gemcitabine and merits further evaluation in a phase II trial." | 2.80 | A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. ( Liljefors, M; Rossmann, E; Ullenhag, GJ, 2015) |
| "Capecitabine was administered orally twice a day at a dose of 1, 250 mg/m(2) for 14-day followed by 7-day rest and oral thalidomide 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity." | 2.78 | [Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer]. ( Li, CH; Ma, TH; Shi, SB; Tang, XY, 2013) |
| "To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer." | 2.78 | Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial. ( Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D, 2013) |
| "Pomalidomide is an investigational immunomodulating drug (IMiD) that also inhibits angiogenesis and has direct anti-tumour effects." | 2.76 | A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer. ( Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA, 2011) |
| "Thalidomide was fairly well tolerated in patients with metastatic carcinoid/islet cell tumors, but failed to reveal any objective responses." | 2.73 | Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors. ( Campbell, J; Shah, MH; Varker, KA, 2008) |
| "The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research." | 2.43 | Docetaxel in the management of advanced pancreatic cancer. ( Lopes, G; Rocha Lima, CM, 2005) |
| "Chemotherapies for pancreatic cancer are typically studied for their cytotoxic properties rather than for their ability to increase the immunogenicity of pancreatic tumour cells." | 1.62 | Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells. ( Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y, 2021) |
| "Pomalidomide treatment resulted in downregulation of interferon regulatory factor 4, a transcription factor for M2 macrophage polarization." | 1.51 | Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. ( Bastea, LI; Copland, JA; Doeppler, H; Edenfield, B; Fleming, AK; Li, Z; Liou, GY; Pandey, V; Qiu, Y; Storz, P; Tun, HW; von Roemeling, CA, 2019) |
| "Curative treatment of aggressive Kaposi sarcoma (KS) with conventional chemotherapy in human immunodeficiency virus (HIV)-infected patients remains difficult." | 1.39 | Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma. ( Burg, S; Crickx, B; Di Lucca, J; Feldman, J; Joly, V; Lariven, S; Marinho, E; Maubec, E; Peytavin, G; Raymond, E; Sarda-Mantel, L; Steff, M, 2013) |
| "Thalidomide has been shown to have antiangiogenic and immunomodulatory effects, including the inhibition of vascular endothelial growth factor, basic fibroblast growth factor and tumor necrosis factor alpha." | 1.32 | [A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine]. ( Hada, M; Mizutari, K, 2004) |
| "The prognosis of pancreatic cancer with metastases or recurrence is quite poor." | 1.32 | [A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. ( Hada, M; Mizutari, K, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (45.45) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Nishi, H | 1 |
| Gotoh, K | 1 |
| Tomimaru, Y | 1 |
| Kobayashi, S | 1 |
| Sasaki, K | 1 |
| Iwagami, Y | 1 |
| Yamada, D | 1 |
| Akita, H | 1 |
| Asaoka, T | 1 |
| Noda, T | 1 |
| Takahashi, H | 1 |
| Tanemura, M | 1 |
| Doki, Y | 1 |
| Eguchi, H | 1 |
| Smith, PL | 1 |
| Yogaratnam, Y | 1 |
| Samad, M | 1 |
| Kasow, S | 1 |
| Dalgleish, AG | 4 |
| Bastea, LI | 1 |
| Liou, GY | 1 |
| Pandey, V | 1 |
| Fleming, AK | 1 |
| von Roemeling, CA | 1 |
| Doeppler, H | 1 |
| Li, Z | 1 |
| Qiu, Y | 1 |
| Edenfield, B | 1 |
| Copland, JA | 1 |
| Tun, HW | 1 |
| Storz, P | 1 |
| Shi, SB | 1 |
| Ma, TH | 1 |
| Tang, XY | 1 |
| Li, CH | 1 |
| Steff, M | 1 |
| Joly, V | 1 |
| Di Lucca, J | 1 |
| Feldman, J | 1 |
| Burg, S | 1 |
| Sarda-Mantel, L | 1 |
| Peytavin, G | 1 |
| Marinho, E | 1 |
| Crickx, B | 1 |
| Raymond, E | 1 |
| Lariven, S | 1 |
| Maubec, E | 1 |
| Ullenhag, GJ | 2 |
| Rossmann, E | 1 |
| Liljefors, M | 2 |
| Kuroda, H | 1 |
| Yoshida, M | 1 |
| Usami, M | 1 |
| Shimoyama, S | 1 |
| Sakamoto, H | 1 |
| Yamada, M | 1 |
| Fujii, S | 1 |
| Maeda, M | 1 |
| Fujita, M | 1 |
| Kanari, Y | 1 |
| Sato, T | 1 |
| Kato, J | 1 |
| Mozaffari, F | 1 |
| Broberg, M | 1 |
| Mellstedt, H | 1 |
| Liu, WM | 1 |
| Nizar, S | 1 |
| Infante, JR | 2 |
| Jones, SF | 1 |
| Bendell, JC | 2 |
| Spigel, DR | 2 |
| Yardley, DA | 1 |
| Weekes, CD | 1 |
| Messersmith, WA | 1 |
| Hainsworth, JD | 2 |
| Burris, HA | 2 |
| Fryer, RA | 1 |
| Barlett, B | 1 |
| Galustian, C | 1 |
| Arkenau, HT | 1 |
| Rubin, MS | 1 |
| Waterhouse, D | 1 |
| Jones, GT | 1 |
| Lane, CM | 1 |
| Marriott, JB | 1 |
| Clarke, IA | 1 |
| Czajka, A | 1 |
| Dredge, K | 1 |
| Childs, K | 1 |
| Man, HW | 1 |
| Schafer, P | 1 |
| Govinda, S | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Hada, M | 2 |
| Mizutari, K | 2 |
| Stroud, M | 1 |
| Gordon, JN | 1 |
| Trebble, TM | 1 |
| Ellis, RD | 1 |
| Duncan, HD | 1 |
| Johns, T | 1 |
| Goggin, PM | 1 |
| Lopes, G | 1 |
| Rocha Lima, CM | 1 |
| Kulke, MH | 1 |
| Stuart, K | 1 |
| Enzinger, PC | 1 |
| Ryan, DP | 1 |
| Clark, JW | 1 |
| Muzikansky, A | 1 |
| Vincitore, M | 1 |
| Michelini, A | 1 |
| Fuchs, CS | 1 |
| Varker, KA | 1 |
| Campbell, J | 1 |
| Shah, MH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I/II Study of Lenalidomide and Gemcitabine as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer[NCT01547260] | Phase 1/Phase 2 | 34 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| A Phase I/II Study of CC-4047 in Combination With Gemcitabine in Subjects With Untreated Advanced Carcinoma of the Pancreas[NCT00540579] | Phase 1/Phase 2 | 23 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The relative incidence of Grade 3/4 adverse events from protocol treatment as defined by Common Terminology Criteria for Adverse Events v3.0 (CTCAE) (NCT00540579)
Timeframe: 24 Months
| Intervention | percentage of patients (Number) |
|---|---|
| Pomalidomide/Gemcitabine | 39 |
"Unacceptable side effects or dose-limiting toxicities (DLTs) were defined as follows:~Inability to Complete cycle 1 of therapy due to drug-related toxicity.~> Grade 3 non-hematological drug-related toxicity (excluding alopecia) despite optimal supportive care~Febrile neutropenia (absolute neutrophil count [ANC] <1,000/μL and fever >101° F (38.5° C))~Grade 4 neutropenia that occurs prior to day 21. (Grade 4 neutropenia that occurs after day 21 but resolves within 7 days of the scheduled cycle 2, will not be considered DLT)~Platelet count < 25,000/μL~Inability to initiate Cycle 2, Day 1 therapy within 7 days of scheduled start (i.e. cannot delay the start of Cycle 2 by more than 7 days following the normal 7 day recovery period) due to drug-related toxicity." (NCT00540579)
Timeframe: 6 months
| Intervention | milligrams (Number) | |
|---|---|---|
| Pomalidomide | Gemcitabine | |
| Pomalidomide/Gemcitabine | 10 | 1000 |
2 reviews available for thalidomide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Thalidomide and cancer cachexia: old problem, new hope?
Topics: Angiogenesis Inhibitors; Cachexia; Humans; Neoplasms; Pancreatic Neoplasms; Thalidomide | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cap | 2005 |
8 trials available for thalidomide and Pancreatic Neoplasms
| Article | Year |
|---|---|
[Effect of second-line treatment with capecitabine and thalidomide in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; | 2013 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Pro | 2015 |
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lym | 2017 |
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Dru | 2011 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disea | 2013 |
Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
Topics: Aged; Angiogenesis Inhibitors; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Nut | 2005 |
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; An | 2006 |
Phase II study of thalidomide in patients with metastatic carcinoid and islet cell tumors.
Topics: Adenoma, Islet Cell; Adult; Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoid Tumor; Chrom | 2008 |
12 other studies available for thalidomide and Pancreatic Neoplasms
| Article | Year |
|---|---|
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidin | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidin | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidin | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidin | 2023 |
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD8-Pos | 2021 |
Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions.
Topics: Animals; Humans; Immunologic Factors; Interferon Regulatory Factors; Macrophages; Mice; Pancreatic N | 2019 |
Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.
Topics: AIDS-Related Opportunistic Infections; Angiogenesis Inhibitors; Antiretroviral Therapy, Highly Activ | 2013 |
[A Newly Diagnosed Case of Multiple Myeloma in Which Lenalidomide Was Continued after Surgery for a Pancreatic Neuroendocrine Tumor That Developed during Lenalidomide Maintenance Therapy].
Topics: Aged; Female; Humans; Lenalidomide; Multiple Myeloma; Neoplasms, Second Primary; Pancreatic Neoplasm | 2015 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcita | 2010 |
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; De | 2011 |
Bibliography. Current world literature. Therapeutic modalities.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dip | 2002 |
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associa | 2003 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase 2; Dru | 2004 |
Thalidomide slows wasting in some pancreatic cancers.
Topics: Body Weight; Humans; Pancreatic Neoplasms; Thalidomide; Wasting Syndrome | 2005 |